^
Association details:
Biomarker:KRAS G12V
Cancer:Solid Tumor
Drug:AFNT-211 (TCR modulator, KRAS G12V inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Excerpt:
...Confirmed KRAS G12V mutational status and HLA-A*11:01 allele 2....
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.

Published date:
05/25/2023
Excerpt:
AFNT-211 was assessed for efficacy in vitro against a panel of KRASG12V-expressing tumor cell lines and in vivo using human xenograft mouse models….Coculture of AFNT-211 with a panel of KRASG12V-expressing tumor cell lines led to significant effector cytokine secretion, T cell proliferation, and tumor cell killing....Potent anti-tumor response was observed in vivo in a mouse xenograft model….
DOI:
10.1200/JCO.2023.41.16_suppl.2543